Triple-Drug attack aims to shrink head and neck tumors
NCT ID NCT07509099
First seen Apr 06, 2026 · Last updated May 06, 2026 · Updated 5 times
Summary
This study tests whether adding a targeted drug (cetuximab) to standard immunotherapy (pembrolizumab or finotonlimab) and chemotherapy can help people with advanced head and neck cancer live longer without their cancer growing. About 316 adults aged 18-70 whose cancer has spread or returned will be randomly assigned to receive either the three-drug combo or just immunotherapy plus chemo. The main goal is to see if the triple therapy delays cancer progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.